Clinical observation of albumin-bound paclitaxel plus nedaplatin as first-line treatment in advanced esophageal squamous cell carcinoma patients

颜　芳; 应明真; 陈龙佩; 傅　强

doi:10.19401/j.cnki.1007-3639.2020.08.011

您当前的位置：

首页 >

文章列表页 >

Clinical observation of albumin-bound paclitaxel plus nedaplatin as first-line treatment in advanced esophageal squamous cell carcinoma patients

更新时间：2026-01-27

- Clinical observation of albumin-bound paclitaxel plus nedaplatin as first-line treatment in advanced esophageal squamous cell carcinoma patients
- China Oncology Vol. 30, Issue 8, Pages: 632-635(2020)
- 作者机构：
  
  海军军医大学附属长海医院肿瘤科,上海,200433
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2020.08.011
  CLC： R735.1
- Published Online：04 September 2020，
  
  Published：04 September 2020
- 稿件说明：
移动端阅览
颜　芳, 应明真, 陈龙佩, 傅　强. 白蛋白结合型紫杉醇联合奈达铂一线治疗晚期食管癌患者的临床观察[J]. 中国癌症杂志, 2020, 30(8): 632-635.

颜　芳, 应明真, 陈龙佩, et al. Clinical observation of albumin-bound paclitaxel plus nedaplatin as first-line treatment in advanced esophageal squamous cell carcinoma patients[J]. China Oncology, 2020, 30(8): 632-635.
颜　芳, 应明真, 陈龙佩, 傅　强. 白蛋白结合型紫杉醇联合奈达铂一线治疗晚期食管癌患者的临床观察[J]. 中国癌症杂志, 2020, 30(8): 632-635. DOI： 10.19401/j.cnki.1007-3639.2020.08.011.

颜　芳, 应明真, 陈龙佩, et al. Clinical observation of albumin-bound paclitaxel plus nedaplatin as first-line treatment in advanced esophageal squamous cell carcinoma patients[J]. China Oncology, 2020, 30(8): 632-635. DOI： 10.19401/j.cnki.1007-3639.2020.08.011.

摘要

背景与目的：化疗是晚期食管癌患者的主要治疗手段，但目前尚没有标准的一线治疗方案，通过白蛋白结合型紫杉醇联合奈达铂方案治疗晚期食管癌，评价其临床疗效及安全性。方法：收集2016年2月—2019年2月之间在长海医院诊治的晚期食管癌并有可评价病灶的患者31例，一线予以白蛋白结合型紫杉醇联合奈达铂方案化疗，具体用药为：白蛋白结合型紫杉醇130 mg/m

，第1、8天；奈达铂70 mg/m

，第1天；每3周重复。采用实体瘤疗效评价标准（Response Evaluation Criteria in Solid Tumors，RECIST）1.1标准评估疗效，按照美国国立癌症研究所通用毒性标准（National Cancer Institute Common Toxicity Criteria，NCI-CTC）5.0评估不良反应。结果：全部31例患者均可评价疗效，其中完全缓解（complete response，CR）1例（3.2%），部分缓解（partial response，PR）20例（64.5%），疾病稳定（stable disease，SD）9例（29.0%），疾病进展（progressive disease，PD）1例（3.2%），客观缓解率（objective response rate，ORR）为67.7%，疾病控制率（disease control rate，DCR）为96.8%，中位无进展生存期（progression-free survival，PFS）为9.4个月。常见不良反应主要包括骨髓抑制、感觉神经病变、关节酸痛、肌肉酸痛、消化道反应及脱发，无毒性相关死亡病例。结论：白蛋白结合型紫杉醇联合奈达铂一线治疗晚期食管癌疗效较好，不良反应患者可耐受，值得进一步推广。

Abstract

Background and purpose: Chemotherapy remains the main treatment method for metastatic esophageal squamous cell carcinoma (ESCC). However

no standard regimen has b

een established as first-line therapy for metastatic ESCC. The purpose of this study was to observe the clinical efficacy and safety of albumin-bound paclitaxel plus nedaplatin as first-line therapy in patients with metastatic ESCC. Methods: Clinical outcomes of 31 patients with metastatic ESCC in Changhai Hospital between Feb. 2016 and Feb. 2019 were analyzed. These patients received albumin-bound paclitaxel combined with nedaplatin as first-line therapy. Albumin-bound paclitaxel was administered at a dose of 130 mg/m

on day 1 and 8 of a 21-day cycle. Nedaplatin was administered at a dose of 70 mg/m

on day 1 of a 21-day cycle. Evaluation of tumor response was performed according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1). Toxicities were graded using version of the National Cancer Institute Common Toxicity Criteria (NCI-CTC) 5.0. Results: All patients were available for evaluation. Of the 31 patients

1 case (3.2%) got complete response (CR)

20 cases (64.5%) got partial response (PR)

9 cases (29.0%) had stable disease (SD) and 1 case (3.2%) had progressive disease (PD). The objective response rate (ORR) was 67.7%

the disease control rate (DCR) was 96.8% and the median progression-free survival (PFS) was 9.4 months. The main toxicities included hematological toxicity

sensory neuropathy

arthralgia

myalgia

gastrointestinal reactions and alopecia. Conclusion: The combination of albumin-bound paclitaxel and nedaplatin is found to be an effective and tolerable option as first-line therapy for patients with metastatic ESCC.

关键词

Keywords

references

Views

3809

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of liposome binding antisense oligonucleotide BP1003 on albumin-bound paclitaxel sensitivity in pancreatic cancer cells by inhibiting STAT3

The selection and application of platinum drugs in the treatment of head and neck squamous cell carcinomas

Analysis of prognostic factors in 99 patients with extranodal NK/T cell lymphoma

Spatial dynamic distribution and stability of¹⁸F-FDG uptake locations within primary tumor during radiotherapy for esophageal squamous cell carcinoma

A clinical study of rhG-CSF of different dosages in preventing leukopenia after chemotherapy in patients with advanced non-small cell lung cancer

Related Author

Dinghua YANG

Xin SONG

Rongmin CAI

Guochao ZHOU

Hua FU

李文成

王孝深

吴晓琳

Related Institution

Department of Hepatology and Gallbladder, Xiangxi Autonomous Prefecture People’s Hospital, Xiangxi

安徽医科大学第一附属医院放疗科

复旦大学附属肿瘤医院放疗科，复旦大学上海医学院肿瘤学系

河北医科大学第四医院放疗科

复旦大学附属肿瘤医院放射治疗中心，复旦大学上海医学院肿瘤学系

AI问答

⁰